Amphastar Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Amphastar Pharmaceuticals, Inc. reported a slight revenue decline in 2025 to $719.9 million, down 2% from 2024, with net income decreasing to $98.1 million, while launching new products and expanding its pipeline.
NASDAQ
Amphastar Pharmaceuticals announces increased net revenues and net income for 2024, fueled by BAQSIMI, Primatene MIST, and other key products.
NASDAQ
Amphastar Pharmaceuticals reports a significant increase in net revenues and net income for 2023, fueled by strong sales of key products and the acquisition of BAQSIMI.